No Data
No Data
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus Out Licenses Canadian Rights to Cancer Drug Loqtorzi
Express News | Coherus BioSciences - Apotex Agreed to Pay to Co USD Equivalent of up to Aggregate of up to $51.5 Mln Canadian Dollars in Milestone Payments
Express News | Coherus BioSciences Inc - Apotex Agreed to Pay to Company an Upfront Payment of $6.25 Mln United States Dollars
Express News | Coherus BioSciences Inc - Has Granted to Apotex an Exclusive License Under Co's Rights to Toripalimab to Commercialize Toripalimab Within Canada
Express News | Coherus BioSciences Inc - on June 27, Entered Into an Exclusive License and Distribution Agreement With Apotex, Inc
No Data